Hims Hers Health Inc (HIMS) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Hims Hers Health Inc stock $5.36, price $26.00, that is 79.4% below the price, quality 47 out of 100. Rating: strongly overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range $3.11 – $68.74 · fair‑value band $2.87 – $7.86 · the $26.00 price screens above the $5.36 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Hims Hers Health in your weekly email
Every Wednesday you see whether Hims Hers Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally.
Show moreShow less
The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.
It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers.
Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health.
The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.
Stock analysis
Hims Hers Health Inc (HIMS) currently trades at $26.00, while our model-based Fair Value estimate is $5.36, 79% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $26.51 per share, and 2 of the 23 models we run sit above the $26.00 price.
Bear case: the Economic Profit group reads lowest at $2.12, and 21 of the 23 models stay below the price. Data coverage for this calculation is low.
Scenario range: $2.87 (bear) to $7.86 (bull), the price of $26.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Hims Hers Health Inc reported revenue of $2.3B in FY2025 versus $272M in FY2021, a compound +71.4%/yr. Reported net income was $128M in FY2025.
Key figures
Market cap $6.1B Mid · P/S ratio 2.64 · EPS (TTM) $−0.6400 · Net margin −5.5% · Return on equity −32.0% · Return on assets (EBIT) −7.8% (5-year average) · Operating margin −12.8% · Revenue (TTM) $2.6B.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 37% below its 52-week high and 79% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −79%, HIMS screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely ($0.1700 to $27.06). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear$2.87Fair Value $5.36Bull$7.86
Price $26.00 · Downside -79.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, one officer or director bought shares worth $1.2M, on May 26, 2026. Over the same period, 7 people sold shares worth $9.9M.
SaleSoleil BoughtonChief Legal Officer11× since Nov 10, 2025: 69,383 shares, avg. $27.94$1.9MOct 28, 202610b5-1 plan
SaleOluyemi OkupeChief Financial Officer18× since Nov 17, 2025: 311,212 shares, avg. $31.12$9.7MOct 1, 202610b5-1 plan
SaleMichael ChiChief Operating Officer4× since Dec 17, 2025: 139,093 shares, avg. $26.94$3.7MSep 15, 202610b5-1 plan
SaleMohamed ElshenawyCTO2× since Jun 17, 2026: 37,994 shares, avg. $30.85$1.2MSep 15, 202610b5-1 plan
SaleDeborah M. AutorChief Policy Officer, Director2× since Dec 17, 2025: 23,827 shares, avg. $30.47$726,080Aug 18, 202610b5-1 plan
SalePatrick Harrison CarrollChief Medical Officer2× since Dec 17, 2025: 33,747 shares, avg. $35.51$1.2MJun 18, 202610b5-1 plan
SaleIrene BecklundPAO3× since Dec 17, 2025: 26,003 shares, avg. $31.37$815,797Jun 17, 202610b5-1 plan
BuyDavid B WellsDirector48,400 shares at $24.24$1.2MMay 26, 2026
SaleGarcia Andrea G PerezDirector2,500 shares at $39.17$97,925Dec 9, 2025
Plus 35 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.85/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+59.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+64.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+73.6%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+89.6%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10.2% (2020) → 4.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed
Growth Forecast
A lot of optimism in the price
The price assumes less growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+45.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+23.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +42.3% a year for the price and +20.6% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (91 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
AI conclusion: Rapid revenue growth via telehealth subscriptions forms the main strength, while limited pricing power plus regulatory uncertainty from lawsuits remain the key weakness.
Main risk: The FTC lawsuit alleging deceptive privacy practices, data sharing with advertisers and difficult subscription cancellations could force operational changes that reduce customer acquisition and retention.
Bull case: By resolving the FTC matter through improved disclosures and leveraging its AI platform for efficiency, Hims could strengthen customer trust and expand profitably into new therapies and markets.
Bear case: If regulatory actions impose strict limits on subscription practices and data use while rivals like Ro capture more customers, Hims could face sustained margin pressure and slower growth in its core offerings.
Hims & Hers continues to deliver rapid revenue growth through its telehealth subscriptions, yet gross margins have compressed for two straight years amid a shift to lower-margin weight-loss products and international expansion. Multiple class-action lawsuits and an outstanding FTC complaint create ongoing regulatory uncertainty for its direct-to-consumer approach. Our models see the shares as overvalued. Will the new Lilly partnership strengthen the core model more than legal and margin pressures weaken it?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 2/11 measures
Overall it trails its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside−79.4% · Bottom 25%
Profitability
Return on assets6.0% · Above median
Net margin (12 months)−5.5% · Bottom 25%
Operating margin (12 months)−12.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)38.2% · Top 25%
Balance sheet
Debt / equity1.80× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Hims Hers Health Inc Fair Value". https://www.fairvalue-calculator.com/stock/HIMS
Frequently asked questions
Is Hims Hers Health Inc (HIMS) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of $5.36 versus a price of $26.00, about 79% lower (overvalued).
What is the fair value of HIMS?
Our model-based fair value for Hims Hers Health Inc is $5.36 (as of Nov 9, 2026), built from audited fundamentals. The current price: $26.00.
What is the quality score of HIMS?
Hims Hers Health Inc has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hims Hers Health Inc (HIMS)?
Our model-based price target is the fair value of $5.36 (as of Nov 9, 2026) from 23 valuation models. Cautious scenario $2.87, optimistic scenario $7.86. It is a calculation from audited fundamentals, not an analyst target.
What is the Hims Hers Health Inc stock forecast for 2026?
Our models put fair value at $5.36, about 79% lower versus a price of $26.00 (overvalued). Cautious scenario $2.87, optimistic scenario $7.86. The calculation is refreshed regularly with new filings.
What is the revenue of Hims Hers Health Inc (HIMS)?
Hims Hers Health Inc reported trailing-twelve-month revenue of about $2.6B (latest available figure, as of Nov 9, 2026).
What growth is priced into Hims Hers Health Inc (HIMS)?
For today's price to be fair in a discounted-cash-flow model, Hims Hers Health Inc would have to grow free cash flow by +45.7 % per year for five years (discount rate 12.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +73.6 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of HIMS use?
Our models discount Hims Hers Health Inc at 12.2 %: a base by market capitalisation (mid), damped by beta 2.43, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Hims Hers Health Inc that is +45.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.2 %) and the same formula as our fair value.
How much growth has Hims Hers Health Inc (HIMS) delivered so far?
Over the past 5 years revenue at Hims Hers Health Inc grew +73.6 % a year. The price currently implies free-cash-flow growth of +45.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Hims Hers Health Inc (HIMS) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Hims Hers Health Inc (+45.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Hims Hers Health Inc (HIMS)?
The free-cash-flow yield on the price is 1.23 %: that much free cash flow Hims Hers Health Inc produces per unit of market value. When it exceeds the discount rate of our models (12.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Hims Hers Health Inc (HIMS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hims Hers Health Inc it is $5.36 per share (as of Nov 9, 2026), against a price of $26.00. It is the blended result of 23 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Hims Hers Health Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, HIMS trades above its calculated fair value: price $26.00, fair value $5.36, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HIMS?
No. The price is what the market pays today ($26.00); the fair value is what the company's own numbers justify ($5.36). For Hims Hers Health Inc the two are $20.64 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hims Hers Health Inc worth?
The market values Hims Hers Health Inc at about $6.1B (market capitalisation, as of Nov 9, 2026). Per share that is $26.00; our models calculate a fair value of $5.36 per share.
What do the bullish and bearish scenarios say about HIMS?
Our models span a range for Hims Hers Health Inc: cautious scenario $2.87, base $5.36, optimistic $7.86 per share (as of Nov 9, 2026, price $26.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of HIMS?
The PEG ratio of Hims Hers Health Inc is 2.59 (P/E divided by earnings growth, as of Nov 9, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Hims Hers Health Inc (HIMS)?
Balance-sheet figures for Hims Hers Health Inc (as of Nov 9, 2026): return on equity −32.0%, debt of 1.80 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is HIMS from its 52-week high?
Hims Hers Health Inc trades at $26.00, about 37% below its 52-week high of $41.52 and 79% above the low of $14.52 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $5.36 is for.
Which stocks are comparable to Hims Hers Health Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hims Hers Health Inc stock attractive at the current price?
The data as of Nov 9, 2026: price $26.00, calculated fair value $5.36 (−79%), Quality Score 47/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HIMS calculated?
We run Hims Hers Health Inc through 23 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $5.36 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Hims Hers Health Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hims Hers Health Inc (HIMS)?
The closing price on Nov 6, 2026 was $26.00. Our model-based fair value is $5.36, about 79% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hims Hers Health Inc right now?
The price sits above even our optimistic bull case ($7.86). The favourable scenario is already priced in. Weak quality (47/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide ($2.87 to $7.86). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Hims Hers Health Inc
How large is the market capitalisation of Hims Hers Health Inc (HIMS)?
The market capitalisation of Hims Hers Health Inc is $6.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hims Hers Health Inc (HIMS)?
The price-to-sales ratio of Hims Hers Health Inc is 2.64 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hims Hers Health Inc (HIMS)?
Earnings per share at Hims Hers Health Inc are $−0.6400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Hims Hers Health Inc (HIMS)?
The net margin of Hims Hers Health Inc is −5.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hims Hers Health Inc (HIMS)?
The return on equity (ROE) of Hims Hers Health Inc is −32.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hims Hers Health Inc (HIMS)?
On an EBIT basis the return on assets of Hims Hers Health Inc is −7.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hims Hers Health Inc (HIMS)?
The operating margin of Hims Hers Health Inc is −12.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hims Hers Health Inc (HIMS)?
Revenue at Hims Hers Health Inc is growing +38.2% versus a year earlier (3y avg +64.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hims Hers Health Inc (HIMS)?
Earnings per share at Hims Hers Health Inc are growing −17.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Hims Hers Health Inc (HIMS) carry?
The net debt of Hims Hers Health Inc is $1.0B (fiscal year 2025, ≈ 14.0 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Hims Hers Health Inc in the live analysis
One click puts Hims Hers Health Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026